Holen Sie sich die Stockscreener-App
185.35
0.22%
0.4755
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$184.87
Offen:
$183.91
24-Stunden-Volumen:
196.94K
Relative Volume:
0.12
Marktkapitalisierung:
$27.20B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
21.05
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
-1.47%
1M Leistung:
-4.40%
6M Leistung:
+29.03%
1J Leistung:
+23.21%
1-Tages-Spanne:
$182.60
$186.27
1-Wochen-Bereich:
$181.24
$190.99
52-Wochen-Spanne:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, NVS, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
185.32 | 27.13B | 9.53B | 1.29B | 1.97B | 8.8057 |
|
LLY
Lilly Eli Co
|
996.61 | 884.36B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.83 | 579.34B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
225.60 | 406.87B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
NVS
Novartis Ag Adr
|
161.00 | 305.53B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
193.24 | 301.19B | 58.80B | 10.24B | 8.98B | 3.2788 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen CEO touts “new era of growth” at TD Cowen as 10 Phase 3 programs near key readouts - Yahoo Finance
Biogen Inc (BIIB) Shares Gap Down to $181.74 on Mar 6 - GuruFocus
Health Rounds: Protein related to Parkinson's linked to faster Alzheimer's progression in women - marketscreener.com
Biogen/Stoke’s zorevunersen hailed as potential first disease-modifying drug for rare epilepsy - European Pharmaceutical Review
Spinal muscular atrophy research progresses at 2026 MDA Conference, Biogen asserts - Traders Union
What Makes Biogen (BIIB) an Attractive Long-Term Holding? - Insider Monkey
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences - Biogen
(BIIB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - Biogen
Elo Mutual Pension Insurance Co Boosts Biogen Stake - National Today
BIIB Earnings History & Surprises | EPS & Revenue Results | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Evaluating Alzheimer's Disease Treatments - Seeking Alpha
Biogen Inc. $BIIB Shares Sold by Fisher Asset Management LLC - MarketBeat
Biogen : to Participate in the Leerink Global Healthcare Conference 2026 - marketscreener.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Biogen to Participate in the Leerink Global Healthcare Conference 2026 - Biogen
BIIB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rafferty Asset Management Reduces Biogen Stake - National Today
Biogen at TD Cowen Conference: Strategic Expansion and Challenges - Investing.com India
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Inc. (BIIB) Stock Analysis: Evaluating the 7.22% Upside Potential Amidst Market Dynamics - DirectorsTalk Interviews
Biogen Deepens Its ALS Footprint With Long-Term Qalsody Safety Registry - TipRanks
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
TD Asset Management Inc Increases Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Rafferty Asset Management LLC Lowers Stake in Biogen Inc. $BIIB - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Has $43.06 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen’s BIIB080 Readout Tests Alzheimer’s Hopes And Investor Sentiment - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Biogen (BIIB) Receives a Buy from RBC Capital - The Globe and Mail
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Generali Investments Management Co LLC Grows Holdings in Biogen Inc. $BIIB - MarketBeat
Fox Run Management L.L.C. Has $976,000 Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Average Rating of "Hold" by Brokerages - MarketBeat
Biogen Trial Updates Test Investor Views On Pipeline Strength And Valuation - Sahm
AMETHYST trial of litifilimab making "strong progress," Biogen says - Lupus News Today
Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says - marketscreener.com
Primecap Management Co. CA Has $2.09 Billion Stock Holdings in Biogen Inc. $BIIB - MarketBeat
10,006 Shares in Biogen Inc. $BIIB Acquired by K.J. Harrison & Partners Inc - MarketBeat
Dakota Wealth Management Acquires New Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Stock After Alzheimer’s Shake-Up: Bargain or Value Trap? - AD HOC NEWS
March 2027 Options Now Available For Biogen (BIIB) - Nasdaq
Biogen to Participate in the TD Cowen 46th Annual Health Care Conference - Biogen
Biogen Inc. (NASDAQ: BIIB) Q4 2025 earnings call transcript - MSN
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Here Are Thursday’s Top Wall Street Analysts Research Calls: Amazon.com, Biogen, Caterpillar, e.l.f. Beauty, Southern Company and More - AOL.com
Dementia Treatment Market Booming with Rapid Growth Through - openPR.com
Biogen Pharmachem Industries Ltd is Rated Strong Sell - Markets Mojo
How (BIIB) Movements Inform Risk Allocation Models - Stock Traders Daily
Biogen Receives Honorable Mention From Fast Company's World Changing Ideas Awards - CSRwire
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
2.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):